Forskning ved Københavns Universitet - Københavns Universitet

Forside

Binding of the Multimodal Antidepressant Drug Vortioxetine to the Human Serotonin Transporter

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Binding of the Multimodal Antidepressant Drug Vortioxetine to the Human Serotonin Transporter. / Andersen, Jacob; Ladefoged, Lucy Kate; Wang, Danyang; Kristensen, Trine N Bjerre; Bang-Andersen, Benny; Kristensen, Anders S; Schiøtt, Birgit; Strømgaard, Kristian.

I: A C S Chemical Neuroscience, Bind 6, Nr. 11, 18.11.2015, s. 1892-900.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Andersen, J, Ladefoged, LK, Wang, D, Kristensen, TNB, Bang-Andersen, B, Kristensen, AS, Schiøtt, B & Strømgaard, K 2015, 'Binding of the Multimodal Antidepressant Drug Vortioxetine to the Human Serotonin Transporter', A C S Chemical Neuroscience, bind 6, nr. 11, s. 1892-900. https://doi.org/10.1021/acschemneuro.5b00225

APA

Andersen, J., Ladefoged, L. K., Wang, D., Kristensen, T. N. B., Bang-Andersen, B., Kristensen, A. S., ... Strømgaard, K. (2015). Binding of the Multimodal Antidepressant Drug Vortioxetine to the Human Serotonin Transporter. A C S Chemical Neuroscience, 6(11), 1892-900. https://doi.org/10.1021/acschemneuro.5b00225

Vancouver

Andersen J, Ladefoged LK, Wang D, Kristensen TNB, Bang-Andersen B, Kristensen AS o.a. Binding of the Multimodal Antidepressant Drug Vortioxetine to the Human Serotonin Transporter. A C S Chemical Neuroscience. 2015 nov 18;6(11):1892-900. https://doi.org/10.1021/acschemneuro.5b00225

Author

Andersen, Jacob ; Ladefoged, Lucy Kate ; Wang, Danyang ; Kristensen, Trine N Bjerre ; Bang-Andersen, Benny ; Kristensen, Anders S ; Schiøtt, Birgit ; Strømgaard, Kristian. / Binding of the Multimodal Antidepressant Drug Vortioxetine to the Human Serotonin Transporter. I: A C S Chemical Neuroscience. 2015 ; Bind 6, Nr. 11. s. 1892-900.

Bibtex

@article{356dbde3e4b1487592feef9281870783,
title = "Binding of the Multimodal Antidepressant Drug Vortioxetine to the Human Serotonin Transporter",
abstract = "Selective inhibitors of the human serotonin transporter (hSERT) have been first-line treatment against depression for several decades. Recently, vortioxetine was approved as a new therapeutic option for the treatment of depression. Vortioxetine represents a new class of antidepressant drugs with a multimodal pharmacological profile that in addition to potent inhibition of hSERT include agonistic or antagonistic effects at different serotonin receptors. We used a combination of computational, chemical, and biological methods to decipher the molecular basis for high affinity binding of vortioxetine in hSERT. X-ray crystal structures of the bacterial amino acid transporter LeuT and the Drosophila melanogaster dopamine transporter were used to build homology models of hSERT. Comparative modeling and ligand docking suggest that vortioxetine can adopt several distinct binding modes within the central binding site of hSERT. To distinguish between the identified binding modes, we determined the effect of 57 functional hSERT point mutants on vortioxetine potency and characterized seven structurally related analogs of vortioxetine in a subset of the point mutants. This allowed us to determine the orientation of vortioxetine within the central binding site and showed that only one of the proposed binding modes is functionally relevant. The findings provide important new insight about the molecular basis for high affinity recognition of vortioxetine in hSERT, which is essential for future structure-based drug discovery of novel multimodal drugs with fine-tuned selectivity across different transporter and receptor proteins in the human brain.",
author = "Jacob Andersen and Ladefoged, {Lucy Kate} and Danyang Wang and Kristensen, {Trine N Bjerre} and Benny Bang-Andersen and Kristensen, {Anders S} and Birgit Schi{\o}tt and Kristian Str{\o}mgaard",
year = "2015",
month = "11",
day = "18",
doi = "10.1021/acschemneuro.5b00225",
language = "English",
volume = "6",
pages = "1892--900",
journal = "A C S Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "11",

}

RIS

TY - JOUR

T1 - Binding of the Multimodal Antidepressant Drug Vortioxetine to the Human Serotonin Transporter

AU - Andersen, Jacob

AU - Ladefoged, Lucy Kate

AU - Wang, Danyang

AU - Kristensen, Trine N Bjerre

AU - Bang-Andersen, Benny

AU - Kristensen, Anders S

AU - Schiøtt, Birgit

AU - Strømgaard, Kristian

PY - 2015/11/18

Y1 - 2015/11/18

N2 - Selective inhibitors of the human serotonin transporter (hSERT) have been first-line treatment against depression for several decades. Recently, vortioxetine was approved as a new therapeutic option for the treatment of depression. Vortioxetine represents a new class of antidepressant drugs with a multimodal pharmacological profile that in addition to potent inhibition of hSERT include agonistic or antagonistic effects at different serotonin receptors. We used a combination of computational, chemical, and biological methods to decipher the molecular basis for high affinity binding of vortioxetine in hSERT. X-ray crystal structures of the bacterial amino acid transporter LeuT and the Drosophila melanogaster dopamine transporter were used to build homology models of hSERT. Comparative modeling and ligand docking suggest that vortioxetine can adopt several distinct binding modes within the central binding site of hSERT. To distinguish between the identified binding modes, we determined the effect of 57 functional hSERT point mutants on vortioxetine potency and characterized seven structurally related analogs of vortioxetine in a subset of the point mutants. This allowed us to determine the orientation of vortioxetine within the central binding site and showed that only one of the proposed binding modes is functionally relevant. The findings provide important new insight about the molecular basis for high affinity recognition of vortioxetine in hSERT, which is essential for future structure-based drug discovery of novel multimodal drugs with fine-tuned selectivity across different transporter and receptor proteins in the human brain.

AB - Selective inhibitors of the human serotonin transporter (hSERT) have been first-line treatment against depression for several decades. Recently, vortioxetine was approved as a new therapeutic option for the treatment of depression. Vortioxetine represents a new class of antidepressant drugs with a multimodal pharmacological profile that in addition to potent inhibition of hSERT include agonistic or antagonistic effects at different serotonin receptors. We used a combination of computational, chemical, and biological methods to decipher the molecular basis for high affinity binding of vortioxetine in hSERT. X-ray crystal structures of the bacterial amino acid transporter LeuT and the Drosophila melanogaster dopamine transporter were used to build homology models of hSERT. Comparative modeling and ligand docking suggest that vortioxetine can adopt several distinct binding modes within the central binding site of hSERT. To distinguish between the identified binding modes, we determined the effect of 57 functional hSERT point mutants on vortioxetine potency and characterized seven structurally related analogs of vortioxetine in a subset of the point mutants. This allowed us to determine the orientation of vortioxetine within the central binding site and showed that only one of the proposed binding modes is functionally relevant. The findings provide important new insight about the molecular basis for high affinity recognition of vortioxetine in hSERT, which is essential for future structure-based drug discovery of novel multimodal drugs with fine-tuned selectivity across different transporter and receptor proteins in the human brain.

U2 - 10.1021/acschemneuro.5b00225

DO - 10.1021/acschemneuro.5b00225

M3 - Journal article

C2 - 26389667

VL - 6

SP - 1892

EP - 1900

JO - A C S Chemical Neuroscience

JF - A C S Chemical Neuroscience

SN - 1948-7193

IS - 11

ER -

ID: 156344334